New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTGBCI, BIN, ARMS, UNT, ARIA, TDC, SQI, RL, MAS, LNKD, KR, FCH, EXLP, BRSOn The Fly: Analyst Upgrade Summary
Bristow Group (BRS) upgraded to Overweight from Equal Weight at Barclays... Exterran Partners (EXLP) upgraded to Outperform from Neutral at Credit Suisse... Felcor Lodging (FCH) upgraded to Outperform from Market Perform at JMP Securities... Kroger (KR) upgraded to Overweight from Neutral at JPMorgan... LinkedIn (LNKD) upgraded to Outperform from Sector Perform at RBC Capital... Masco (MAS) upgraded to Hold from Underweight at KeyBanc... Ralph Lauren (RL) upgraded to Outperform from Market Perform at Wells Fargo... SciQuest (SQI) upgraded to Buy from Hold at Canaccord... Teradata (TDC) upgraded to Buy from Neutral at Longbow... ARIAD (ARIA) upgraded to Buy from Hold at Maxim... Unit Corp. (UNT) upgraded to Outperform from Sector Perform at Howard Weil... Amyris (AMRS) upgraded to Market Perform from Underperform at Cowen... Progressive Waste (BIN) upgraded to Outperform from Neutral at Credit Suisse... Glacier Bancorp (GBCI) upgraded to Buy from Neutral at DA Davidson.
News For BRS;EXLP;FCH;KR;LNKD;MAS;RL;SQI;TDC;ARIA;UNT;ARMS;BIN;GBCI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:37 EDTARIAARIAD announces CHMP adopts final opinion on Iclusig
ARIAD Pharmaceuticals announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month. The PRAC conducted an 11-month review of the available data on Iclusig and consulted with a scientific advisory group in oncology. This week, the EMA recommended that Iclusig continue to be used in accordance with its already approved indications as a treatment of certain leukaemias and confirmed that the benefit-risk profile of Iclusig continues to be positive in each of these indications. The EMA also recommended additional warnings in the European product information to minimize the risk of vascular events. The company said, "We are now well positioned to complete pricing and reimbursement negotiations in Europe and to ensure that Iclusig is available to appropriate Philadelphia-chromosome positive leukaemia patients."
October 23, 2014
16:47 EDTGBCIGlacier Bancorp reports Q3 EPS 40c, consensus 40c
Subscribe for More Information
October 21, 2014
11:01 EDTTDCAsyadi announces strategic alliance with Teradata
Subscribe for More Information
October 16, 2014
10:38 EDTLNKDLinkedin October volatility elevated into Q3 and growth outlook
Linkedin October weekly call option implied volatility is at 71, November is at 55, December is at 47, January at 44; compared to its 26-week average of 46 according to Track Data, suggesting large near term price movement into the expected release of Q3 results after the market close on October 30.
October 15, 2014
10:02 EDTMASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:09 EDTBRSBristow Group initiated with a Buy at ISI Group
Subscribe for More Information
06:52 EDTMASMasco downgraded to Neutral from Outperform at Macquarie
Subscribe for More Information
06:12 EDTRLNike's Converse sues rivals over 'copycat' design, NY Post reports
Converse, a unit of Nike (NKE), is suing rivals including Ralph Lauren (RL) and Tory Burch, alleging that shoemakers and retailers are copying its iconic design, the New York Post reports. Lawyers for Converse say "We welcome fair competition, but we do not believe companies have a right to copy the trademarked look." The lawsuit seeks unspecified damages and injunctions that would bar the production of the rival shoe models. Reference Link
October 14, 2014
08:40 EDTUNTUnit Corp. upgraded to Buy from Accumulate at KLR Group
Subscribe for More Information
October 13, 2014
10:08 EDTMASOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Equal Weight from Overweight at Stephens... CME Group (CME) downgraded to Market Perform from Outperform at Wells Fargo... Cliffs Natural (CLF) downgraded to Neutral from Overweight at JPMorgan... Dana Holding (DAN) downgraded to Sector Perform from Outperform at RBC Capital... Darden (DRI) downgraded to Neutral from Overweight at Piper Jaffray... Dover (DOV) downgraded to Neutral at RW Baird... DryShips (DRYS) downgraded to Underperform from Outperform at Imperial Capital... Infineon (IFNNY) downgraded to Neutral from Overweight at JPMorgan... J.C. Penney (JCP) downgraded to Sell from Neutral at UBS... Johnson Controls (JCI) downgraded to Outperform from Top Pick at RBC Capital... Juniper (JNPR) downgraded to Hold from Buy at Argus... Kennametal (KMT) downgraded to Market Perform from Outperform at Wells Fargo... Masco (MAS) downgraded to Equal Weight from Overweight at Barclays... New Gold (NGD) downgraded to Neutral from Overweight at JPMorgan... ON Semiconductor (ONNN) downgraded to Sector Perform from Outperform at Pacific Crest... PBF Energy (PBF) downgraded to Underweight from Equal Weight at Barclays... Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo... STMicroelectronics (STM) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Sector Perform at Pacific Crest... VOXX International (VOXX) downgraded to Market Perform from Outperform at Cowen.
08:52 EDTMASUS Building Products & Homebuilding sector lowered at Barclays
Subscribe for More Information
07:15 EDTMASNational Association of Corporate Directors to hold a conference
Subscribe for More Information
05:56 EDTMASMasco downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Masco to Equal Weight citing its preference for companies with commercial exposure. The firm lowered its price target for shares to $26 from $27.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use